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Drug resistance is a common problem in acute leukaemia
(Mickenna et al, 1997). Patients often relapse with unresponsive
disease after an initial response to treatment with cytotoxic drugs
(Rothenberg et al, 1989). The expression of P-glycoprotein (Pgp)
encoded by the MDR1 gene (Deuchars and Ling, 1989), is a well-
known mechanism of multidrug resistance in relapsed acute
leukaemia (Shustik et al, 1995; Bosch and Croop, 1996). The level
of  MDR1 gene expression in acute leukaemia is commonly
increased after chemotherapy (Grogan et al, 1993; Nooter and
Sonneveld, 1994). In addition, there appears to be a direct correla-
tion between expression of the MDR1 gene de novo and outcome
(survival) in this disease (Poeta et al, 1996).
Although the mechanisms underlying the effect of cytotoxic
drugs on MDR1 gene expression and in turn the multidrug resis-
tant (MDR) phenotype remain poorly understood, the acquisition
of Pgp-mediated drug resistance during chemotherapy is usually
thought to be due to the selection of drug-resistant cells
(Chaudhary and Roninson, 1993; Gekeler et al, 1994; Manzano et
al, 1996). Sikic and colleagues have clearly demonstrated this in a
cell line model (Beketic-Oreskovic et al, 1994; Chen et al, 1994;
Dumontet et al, 1996), under conditions in which up-regulation of
Pgp was prevented. Although several attempts have been made to
demonstrate that Pgp expression can be up-regulated, these studies
have generally required long exposure times (72 h or more).
Consequently, the selection of Pgp-expressing cells could not be
ruled out from these studies (Manzano et al, 1996).
However, we have demonstrated that a rapid induction of the
MDR1 gene can occur after the exposure of cells to anthracyclines
in a human MDR cell line (CEM/A7R) known to express low-
level MDR1 mRNA and P-glycoprotein (Hu et al, 1995). The
induction of MDR1 was dose and time related and correlated with
an increase in Pgp expression and drug resistance. The rapid
increase in MDR1 gene expression after exposure to daunorubicin
or epirubicin strongly supported the previous findings that the
MDR1 gene promoter was activated by anti-cancer agents (Kohno
et al, 1989). Similar effects have been reported in rodent cell lines
(Chin et al, 1990; Fardel et al, 1997). This induction of MDR1
gene expression may have an important role in our understanding
and treatment of drug-resistant tumours, as it can be prevented by
cyclosporin A (CyA) and its analogue PSC 833 (Hu et al, 1996).
Alternative approaches designed to overcome the MDR pheno-
type include the use of new lipid-soluble compounds that are not
substrates for Pgp (De Vries et al, 1990; Michieli et al, 1993).
However, the effect of these agents on MDR1 gene expression is
unknown. The present study was designed to investigate whether
two new lipid-soluble anthracyclines, 4-demethoxydaunorubicin
(idarubicin, IDA) and MX2, a new morpholino-anthracycline,
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Street, Melbourne, Vic. 3000, Australiawere able to up-regulate MDR1 gene expression compared with
the classic anthracycline epirubicin (EPI).
MATERIALS AND METHODS
Materials
EPI and IDA and verapamil were obtained commercially from
Farmitalia (Melbourne, Australia). MX2 was a gift from Kirin
Brewery Company (Japan). Verapamil was dissolved in 0.9%
saline solution. PSC 833 was obtained from Sandoz Pharma (Basel,
Swizerland) and initially dissolved in absolute alcohol before being
diluted in RPMI-1640 to give a stock solution of 0.5 mg ml–1 (the
final ethanol concentration was 35%). RPMI-1640 was purchased
as a powder (Gibco) and supplemented with 10% fetal calf serum
(FCS) (Trace Biosciences, Melbourne, Australia), gentamicin
(80 mg ml–1), minocycline (1 mg ml–1), Hepes (20 mM), sodium
bicarbonate (0.21%) and glutamine (0.8 mM). Monoclonal anti-
body (mAb) MRK 16 to Pgp was generously provided by
Dr Takashi Tsuruo (Division of Experimental Chemotherapy,
Japanese Foundation for Cancer Research). A fluorescein-labelled
F(ab)2 fragment of sheep anti-mouse IgG was purchased from
Silenus Laboratories (Melbourne, Australia). The cDNA probe
pHDR5A was a gift from Dr M Gottesman and Dr Ira Pastan
(Laboratory of Molecular Biology, National Institutes of Health,
Bethesda, MD, USA). The cDNA glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was a gift from Dr Mark Ross (Ludwig
Institute for Cancer Research, Melbourne, Australia). Propidium
iodide was purchased from Sigma Chemical (St Louis, MO, USA).
Cell lines and drug treatment
The studies were carried out in a variant human T-cell leukaemia
MDR cell line, CEM/A7R. This line was derived from a classic
MDR cell line CEM/A7, selected for low-level doxorubicin
(DOX) resistance by stepwise selection of the parental line,
CCRF-CEM, cultured in increasing concentrations of DOX
(Zalcberg et al, 1994). The resistant line CEM/A7 was maintained
in conditioned medium containing 0.07 mg ml–1 of DOX. The
variant line (now stable for over 3 years) was established by
culturing the CEM/A7 cells in the absence of DOX before being
subcloned and designated as the CEM/A7R line. This line was not
exposed to DOX or other Pgp substrates except in the specific
experiments detailed below. At the time of these experiments, all
lines were mycoplasma-free based on the mycoplasma TC Rapid
kit (Gen-Probe, San Diego, CA, USA).
The CEM/A7R cells in exponential growth phase were
collected 2 days after subculture. The cells were washed, counted
and resuspended in 20 ml of fresh medium to a total cell number of
5 ´ 106–1 ´ 107. The cells were treated with various concentrations
of EPI, IDA and MX2 for 4–24 h, then harvested and washed three
times with cold phosphate-buffered saline (PBS) for the analysis
of MDR1 gene expression. Cell viability was determined (after
staining by trypan blue) using phase-contrast microscopy to detect
cells of abnormal size or granularity. Non-viable cells were
excluded from flow cytometric analysis by propidium iodide
staining.
Growth assays
The sensitivity of each of the cell lines to a variety of chemothera-
peutic drugs was determined by a standard growth inhibition assay
(Tsuruo et al, 1981). Briefly, after determining cell viability, 2 ´
105 of the tested cells were exposed to varying concentrations of
each tested drug in the presence or absence of verapamil (Vp) or
PSC 833 in 12-well plates. The cells were incubated at 37°C in a
humidified chamber containing 5% carbon dioxide in air for 3
days and counted using an automated coulter counter (Hu et al,
1990a). Results are expressed as the increase in cell number of
drug-exposed cells as a percentage of the increase in untreated
control cells. The IC10, IC50 and IC90 for each drug were deter-
mined by calculating the drug concentration required to inhibit cell
growth by 10%, 50% and 90%. Relative resistance represents the
ratio of the IC50 of the resistant CEM/A7R cell line compared with
the parental CCRF-CEM cell line.
RNA extraction and Northern blot analysis
RNA was isolated by the guanidinium thiocyanate method
described by Chomczynski and Sacchi (1987). Twenty micrograms
of total cellular RNA was size fractionated on a 1.5% agarose gel
containing 2.2 M formaldehyde and transferred onto nylon filters
(Hybond-N, Amersham, UK) for MDR1 hybridization. The filters
were probed with the plasmid pHDR5A containing a 1.4-kb MDR1
cDNA (Ueda et al, 1987) and then reprobed with a 32P-labelled
GAPDH cDNA for normalization. The pHDR5A probe predomi-
nantly recognizes the MDR1 gene under the high stringency condi-
tions used in this study. The filters were prehybridized overnight at
42°C in hybridization buffer containing 50% formamide, 5 ´ SSPE
(1 ´ SSPE containing 0.15 M sodium chloride, 0.001 M sodium
dihydrogen phosphate and 0.001 M EDTA), 5 ´ Denhardt’s solution,
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Table 1 Chemosensitivity of the CEM/A7R and parental CCRF-CEM cell lines to EPI, MX2, IDA and 5-FU
CEM/A7R CCRF-CEM
Drug IC10 (mg ml–1)I C 50 (mg ml–1)I C 90 (mg ml–1)I C 10 (mg ml–1)I C 50 (mg ml–1)I C 90 (mg ml–1)
EPI 0.103 ± 0.002 0.373 ± 0.041 (5.4) 0.965 ± 0.035 0.008 ± 0.001 0.075 ± 0.003 0.128 ± 0.02
MX2 0.020 ± 0.002 0.045 ± 0.011 (3.2) 0.107 ± 0.009 0.004 ± 0.001 0.014 ± 0.003 0.043 ± 0.003
IDA 0.003 ± 0.001 0.022 ± 0.008 (3.1) 0.080 ± 0.025 0.002 ± 0.001 0.007 ± 0.001 0.016 ± 0.002
5FU 0.180 ± 0.04 0.51 ± 0.22 (1.0) 2.60 ± 0.230 0.20 ± 0.008 0.454 ± 0.122 2.615 ± 0.235
IC10, IC50 and IC90 were determined as described in the Materials and methods section. Results are expressed as the average concentration (mg ml–1) ± standard
deviation (calculated from three experiments). Each experiment was performed in triplicate. Figures in parentheses represent relative resistance (see ‘Materials
and methods’).0.5% sodium dodecyl sulphate (SDS) and 1% skimmed milk
powder. Hybridization was carried out in the same buffer. The
pHDR5A and GAPDH cDNAs were randomly primed with [a-32P]-
dCTP. Labelled cDNA (106 c.p.m.) was added to each millilitre of
hybridization buffer. The filters were washed sequentially in
2 ´ SSPE with 0.1% SDS at 42°C for 15 min, 1 ´ SSPE with 0.1%
SDS at 65°C for 30 min and finally 0.1 ´ SSPE with 0.1% SDS
at room temperature for 15 min. The filters were then exposed
to radiographic film at –70°C using intensifying screens, or radio-
active signals were quantitated by scanning on a phosphorimager
using Image Quant software (Molecular Dynamics, Melbourne,
Australia).
Pgp expression
Flow cytometry was used to measure Pgp expression. Cells were
collected and washed three times in medium containing 10% FCS.
MRK16, a mAb to an external epitope of Pgp (final concentration
10 mg ml–1), was added to cells at room temperature (RT) for
20 min. A non-specific murine mAb (IgG2a, Becton Dickinson,
Sydney, Australia) was used as the isotype control. After a further
three washes, cell pellets were resuspended in the same volume of
phosphate-buffered saline (PBS) containing 10 ml of a 1:10 dilu-
tion of a fluorescein-conjugated F(ab¢)2 fragment of sheep anti-
mouse IgG antibody (Silenus Laboratories) for 20 min at RT in the
dark. Cells were washed once again (´3) and then analysed in a
FACScan flow cytometer (Becton Dickinson). Mean fluorescence
intensity was recorded for each tested population (after correcting
for non-specific binding) to provide an estimate of relative MRK-
16 binding.
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Figure 1 (A) The effect of PSC 833 on chemosensitivity of CEM/A7R cells
as a function of increasing concentrations of EPI or IDA. Growth curves in
the absence (l l–l l) or presence of 0.1 mM PSC 833 (l–l) as a function of
EPI concentrations and in the absence (s s–s s) or presence (s–s) of 1 mM
PSC 833 as a function of IDA concentrations. (B) The effect of PSC 833 on
the chemosensitivity of CEM/A7R cells as a function of increasing
concentrations of 5-FU or MX2. Growth curves in the absence (s s–s s), (n n–n n)
or presence (s–s), (n–n) of 1 mM PSC 833 as a function of 5-FU and MX2
concentrations respectively
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Figure 2 (A) Effect of increasing doses of EPI over a short time on up-
regulation of MDR1 in the CEM/A7R line. Cells in exponential growth phase
were treated with (or without) 0.1 (IC10), 0.5 (IC50), 1.0 (IC90) mg ml–1 of EPI
for 4–6 h. RNA was extracted and analysed by Northern blotting as
described in the Materials and methods section. The migration of 28s and
18s ribosomal RNA are indicated. The MDR1 mRNA level of the parental,
sensitive CCRF-CEM line represented a negative Pgp control. (B) The
Northern analysis shown in A was scanned on a phosphorimager using
Image Quant Software (Molecular Dynamics). The results were expressed as
the ratio of MDR1 to GAPDH after signals were normalized with respect to
the CCRF-CEM signal. Columns, means of triplicate slot blot analysis; bars
give the standard deviation. Similar dose– and time–response patterns were
seen in a repeat experiment[3H]Daunomycin accumulation
Changes in [3H]daunomycin accumulation were used as a func-
tional assay of Pgp (Hu et al, 1990b). Cells were washed three
times with PBS and resuspended in fresh medium for 1 h at 37°C
in a humidifier before performing drug accumulation studies. The
cells were adjusted to a concentration of 5 ´ 106 ml–1 and viability
assessed with trypan blue. Cells were added to 96-well plates to
give a final number of 5 ´ 105 cells per well and incubated at 37°C
with tracer amounts of [3H]daunomycin (final concentration
1.85  ´ 104 Bq ml–1, 0.05 mg ml–1). The cells were harvested onto
glass-fibre filters at designated times with an automated cell
harvester (Cambridge Technology). The filter papers were dried
and dissolved in 5 ml of a liquid scintillation cocktail (Ultima
Cold, Packard) before radioactivity was measured. All assays were
performed in triplicate.
Statistics
Analysis of variance was used to compare intracellular levels of
[3H]daunomycin after exposure of cells to various experimental
conditions.
RESULTS
Cytotoxicity of IDA, MX2 and 5-FU
The relative cytotoxicity of the two lipid-soluble anthracyclines
IDA and MX2 was compared with the classic anthracycline epiru-
bicin (EPI), as well as the unrelated drug 5-FU – a drug not pumped
by Pgp. The IC10, IC50 and IC90 for each drug were determined in a
3-day growth inhibition assay (Table 1) in the drug-resistant
CEM/A7R and the parental drug-sensitive line CCRF-CEM.
On a weight basis, IDA and MX2 were 17- and eightfold more
active than EPI in the drug-resistant line CEM/A7R and 11- and
fivefold more active than EPI in the parental line CCRF-CEM,
respectively, when comparing doses that inhibited cell growth by
50% (IC50). Relative to the drug-sensitive line, there was a fivefold
increase in resistance to EPI and a threefold increase in the resis-
tance to IDA and MX2 in the drug-resistant line. As expected, no
increase in the resistance to 5-FU was observed in the CEM/A7R
line compared with the parental line (Table 1).
PSC 833 (0.1 mM) dramatically reversed the resistance of the
CEM/A7R line to EPI (Figure 1A). However, the addition of 5 mM
verapamil (data not shown) or 1 mM PSC 833 to the culture
medium only slightly increased the sensitivity of this line to IDA
(Figure 1A), and had no detectable effect on the sensitivity of the
line to MX2 (Figure 1B). Neither modulator had any effect on the
sensitivity of the MDR line to 5-FU (Figure 1B).
Gene expression
The effects of EPI, IDA, MX2 or 5-FU on the induction of the MDR1
gene in the CEM/A7R line were compared at their respective IC10,
IC50 and IC90 concentrations over a 4- or 24-h period of drug expo-
sure. All samples collected for the analysis of MDR1 gene expression
were harvested immediately after drug treatment. The up-regulation
of  MDR1 gene expression by each drug was semiquantitatively
assessed by scanning Northern blots on a phosphorimager.
We had previously demonstrated that 1.5 mg ml–1 of EPI (IC90
concentration) induced the expression of MDR1 mRNA as early as
4 h after such exposure. In the present study, the effect of EPI on
the induction of the MDR1 gene was examined at the IC10 and IC90
concentrations over a short time period (4–6 h). Up-regulation of
MDR1 mRNA was observed over 4–6 h with a two- to fivefold
increase in MDR1 mRNA noted at 0.1 (IC10) and 1.0 (IC90) mg ml–1
of EPI respectively (Figure 2A and B).
The impact of IDA and MX2 on the induction of MDR1 gene
expression was examined at equieffective concentrations over 4 h.
Both drugs induced a similar increase in MDR1 mRNA levels in a
dose-dependent manner (Figure 3). A two- to threefold increase in
MDR1 mRNA was observed at the IC10 (0.002, 0.02 mg ml–1) and
IC50 (0.02, 0.05 mg ml–1) concentrations of IDA and MX2, and a
fivefold increase at the IC90 concentrations (0.08, 0.1 mg ml–1) of
834 XF Hu et al
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Figure 3 Effect of IDA or MX2 on induction of MDR1 gene expression in
the CEM/A7R cells after a 4-h exposure. CEM/A7R cells in exponential
growth phase were treated with and without IDA at the IC10 (0.002 mg ml–1),
IC50 (0.02 mg ml–1), and IC90 (0.08 mg ml–1) levels or MX2 at IC10 (0.02 mg ml–1)
IC50 (0.05 mg ml–1), IC90 (0.1 mg ml–1) for 4 h. RNA was then extracted and
subjected to Northern blot analysis and scanned on a phosphorimager as
described in the Materials and methods section. Results are expressed as
the ratio of MDR1 to GAPDH RNA after signals were normalized with respect
to the CCRF-CEM signal. Columns, means of triplicate analyses of Northern
blots; bars, s.d. These experiments were repeated on three separate
occasions with similar findings. The data presented are representative of one
such experiment
Figure 4 The effects of 5-FU on the induction of the MDR1 gene in the
CEM/A7R line over a 24-h exposure. Cells in exponential growth phase were
treated with (or without) 5-FU at the IC10 (0.2 mg ml–1), IC50 (0.5 mg ml–1), IC90
(2 mg ml–1) or IDA at the IC50 level (0.02 mg ml–1) as a comparison. The 32P-
labelled MDR1 and GAPDH bands were scanned on a phosphorimager
using Image Quant Software (Molecular Dynamics) and the results are
expressed as the ratio of MDR1 to GAPDH RNA after signals were
normalized with respect to the CCRF-CEM signal. Columns, means of
triplicate analyses of Northern blots; bars, s.d. Similar results were seen in
repeated experiment
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1.2IDA and MX2 respectively (Figure 3). When the exposure time
was prolonged up to 24 h, a fivefold increase of MDR1 mRNA
was observed at the IC50 concentrations of IDA (0.02 mg ml–1) or
MX2 (0.05 mg ml–1) (data not shown).
The potential induction of the MDR1 gene by 5-FU was exam-
ined at 0.2, 0.5 and 2.0 mg ml–1 (IC10, IC50 and IC90) levels respec-
tively. Although no obvious increase in MDR1 expression was
observed at any concentration of 5-FU after 4 h (data not shown),
Northern analysis revealed induction had occurred in a dose-
dependent manner after 24 h (Figure 4). A threefold induction
in MDR1 expression was seen at the IC90 level (2 mgm l –1)
compared with the fivefold induction of MDR1 at the IC50 level
(0.02 mg ml–1) of IDA (Figure 4).
For each of the four drugs used in these experiments, treated
cells were stained with trypan blue to assess cells for visible cell
damage. Careful examination using phase-contrast microscopy for
change in cell morphology and/or increased granularity revealed
no visible evidence of cell damage within 4–24 h at any of the drug
concentrations used.
Pgp expression
To determine whether the increased levels of MDR1 mRNA
expression induced by IDA, MX2 and 5-FU were accompanied by
corresponding changes in Pgp levels, antigen density (mean
channel fluorescence or mcf) was measured by flow cytometry.
The CEM/A7R cells were exposed for 24 h to approximately the
IC90 levels of IDA, MX2 (0.1 mg ml–1), 5-FU (2.0 mg ml–1) or EPI
(0.5 mg ml–1) before being subjected to Pgp analysis (Figure 5). In
parallel to the increase in the MDR1 mRNA levels (Figure 3), Pgp
expression was increased five- to sevenfold with EPI, MX2 and
IDA (mcf 36.65, 25.98 and 22.20 respectively) and threefold with
5-FU (mcf 18.74). In comparison, the mcf of untreated CEM/A7R
cells was 4.2.
To examine whether the induction in MDR1 gene expression
was stable, CEM/A7R cells were treated overnight with
0.1 mg ml–1 MX2 (IC90) or 2.0 mg ml–1 5-FU (IC90). The drug
treated cells were then washed three times and allowed to grow in
drug-free medium for either 72 h or 3 weeks before being
subjected to a further analysis of MDR1 mRNA levels (data not
shown) or Pgp expression. In the MX2- and IDA-treated
CEM/A7R cells, Pgp expression remained two- to threefold higher
(mcf 13.50 and 11.09) than the untreated CEM/A7R cells (mcf
4.66) 3 weeks after drug exposure. In contrast, the increased Pgp
levels in cells treated with 5-FU returned to base line (mcf 4.69)
within 72 h of stopping drug treatment (data not shown).
To assess the functional activity of Pgp, [3H]daunomycin
accumulation was determined in the CEM/A7R cells. After an
overnight exposure to EPI (0.5 mg ml–1), IDA (0.1 mg ml–1), MX2
MDR1 induction by anthracycline analogues 835
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Figure 5 Flow cytometric analysis of Pgp expression using MRK-16 binding
(filled histogram) compared with an IgG2a control (unfilled histogram) in the
CEM/A7R line with or without a 24-h exposure to IC90 concentrations of EPI
(1.0 mg ml–1), IDA, MX2 (0.1 mg ml–1) or 5-FU (2.0 mg ml–1) before
measurement of Pgp levels as described in the Materials and methods section
Figure 6 The intracellular levels of [3H]daunomycin measured in the
CEM/A7R cells, 3 weeks after overnight treatment with (or without (l l–l l),
EPI 0.5 mg ml–1 (l–l), 0.1 mg ml–1 IDA (n n–n n), 0.1 mg ml–1 MX2 (s–s) or
2 mg ml–1 5-FU (s s–s s)
Figure 7 The chemosensitivity of untreated (l l–l l) or treated CEM/A7R
cells, 3 weeks after an overnight exposure to 0.5 mg ml–1 of EPI (s–s),
0.1 mg ml–1 of IDA (l–l) and MX2 (n n–n n), and 2 mg ml–1 of 5-FU (s s–s s)
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0 0.25 1.0 0.50 0.75 1.25(0.1 mg ml–1) or 5-FU (2.0 mg ml–1), the cells were maintained in
drug-free medium for 3 weeks before drug accumulation was
quantified. Compared with the untreated CEM/A7R cells, the
intracellular levels of [3H]daunomycin were significantly lower
in the EPI-, IDA- and MX2-treated CEM/A7R cells, but were
unchanged in the 5-FU-treated cells (Figure 6). Growth inhibition
assays also showed a two- to threefold increase in resistance to
EPI in MX2-, IDA- and EPI-treated cells after 3 weeks in drug-
free medium. In contrast, the drug sensitivity of 5-FU-treated cells
was the same as that of untreated CEM/A7R cells (Figure 7).
DISCUSSION
In this report, we investigated whether the two lipid-soluble
anthracycline analogues IDA and MX2 could up-regulate MDR1
gene expression in a human MDR, T-cell leukaemia line,
CEM/A7R, and its parental line, CCRF-CEM. Both drugs are
thought to be poor substrates for Pgp-mediated transport (de Vries
and Zijlstra, 1990; Ross et al, 1995). Initially, we compared the
chemosensitivity (in the presence or absence of Vp or PSC 833) of
each drug in the cell lines.
Verapamil (5 mM) and PSC 833 (1 mM) dramatically decreased
the resistance of the CEM/A7R line to EPI, but had no effect on
the sensitivity of this drug-resistant line to MX2 and only slightly
increased the sensitivity to IDA (Figure 1). These findings are
consistent with the observation that both anthracycline analogues
are highly lipophilic and diffuse rapidly through the cell
membrane to bind to DNA, thereby interfering with the capacity of
cells expressing Pgp to pump these drugs (Horichi et al, 1990;
Watanabe et al, 1991; Berman and McBride, 1992) and thus
overcoming drug resistance. Although IDA and MX2 are less
susceptible to this mechanism of resistance compared with the
drug-sensitive line, detectable levels of resistance to IDA and
MX2 were still observed in the resistant CEM/A7R cells (Table 1).
The effects of IDA, MX2 and 5-FU on the induction of MDR1
gene expression were investigated at equieffective concentrations
with respect to the inhibition of cell growth in a 72-h cell growth
inhibition assay. When MDR1 mRNA expression was analysed by
Northern blotting, a two- to fivefold increase was observed in the
CEM/A7R cells 4 h after treatment with IDA, MX2 or EPI at
concentrations ranging from the IC10 to IC90 level. In contrast, 5-
FU failed to up-regulate MDR1 expression after a 4-h exposure,
although induction of MDR1 gene expression was seen after a 24-
h exposure. The effects of these drugs on MDR1 gene expression
was confirmed by flow analysis, demonstrating a concomitant
increase in Pgp expression. Up-regulation of Pgp expression by
IDA and MX2 was stable, as demonstrated by the increase in Pgp
levels, drug resistance and decrease in drug accumulation in the
IDA- and MX2-treated CEM/A7R cells 3 weeks after the removal
of these agents from the culture medium (Figures 5–7).
Other investigators have reported the up-regulation of MDR1
promoter activity in reporter gene assays by cytotoxic drugs (Kohno
et al, 1989) as well as many other factors (Rohlff and Glazer, 1995).
These findings have been controversial with respect to their rele-
vance in the clinical context, as the endogenous promoter does not
always behave in an analogous manner to the transfected promoter.
For example, Tanimura et al (1992) and Ferrandis and Benard
(1993) have demonstrated that a transfected promoter is active in
drug-sensitive cells in which the endogenous promoter is not active.
Increased MDR1 mRNA and Pgp expression have also been
reported in human cell lines after their exposure to cytotoxic drugs
(Chaudhary and Roninson, 1993; Gekeler et al, 1994). However,
the possibility that selection had occurred could not be excluded
(reviewed in Manzano et al, 1996), as drug-induced MDR1 expres-
sion usually occurred after a 72-h exposure to sublethal concentra-
tions of cytotoxics and was associated with the appearance of
visible morphological cell damage.
The present study was designed to examine the role of the two
anthracycline analogues IDA and MX2 on the up-regulation of
MDR1 gene expression for a range of concentrations (IC10, IC50
and IC90 levels) within 4 and 24 h. In our study, the increase in
MDR1 expression was not related to the appearance of cytological
damage and was seen at concentrations as low as the IC10 level for
each drug.
Up-regulation of MDR1 gene expression has mainly been
observed for drugs which are substrates for Pgp, although one
study demonstrated that a non-Pgp substrate, cytarabine, was able
to induce MDR1 expression (after a 72-h exposure) which was
stable after withdrawal of the drug for more than 6 weeks
(Chaudhary and Roninson, 1993). In this report, we observed that
5-FU, also not a substrate for Pgp, could up-regulate MDR1
mRNA levels. However, this appeared to be a transient increase
because the level of Pgp returned to baseline within 72 h of
removal of the drug. These findings suggest that the mechanism by
which 5-FU acts probably differs from that used by other anthra-
cyclines which result in a sustained increase in Pgp expression.
It is likely that the cellular response to cytotoxic stress is to acti-
vate a number of defence mechanisms via stress response path-
ways (Osborn and Chambers, 1996). The up-regulation of Pgp
expression may represent only one of the results of this response to
these stress mechanisms. However, this finding would not be
expected to confer resistance to IDA or other drugs that are not
pumped by Pgp (Consul et al, 1996; Hargrave et al, 1995). Thus,
the up-regulation of Pgp expression in response to such drugs does
not necessarily confer a survival advantage. In fact, it is generally
accepted that the treatment of relapsed refractory leukaemia with
idarubicin/cytarabine is associated with higher rates of complete
remission and longer survival compared with daunorubicin/cytara-
bine (Carella et al, 1993; Berman, 1993).
The mechanism by which these lipid-soluble anthracyclines, or
indeed the classic Pgp substrate EPI, up-regulate Pgp expression
is not known. The fact that induction can occur rapidly (in 4 h)
strongly suggests that up-regulation involves transcription of the
MDR1 gene, perhaps involving stress response pathways. Osborn
and Chambers (1996) demonstrated that a c-jun NH2-terminal
protein kinase (JNK), a member of the mitogen-activated protein
kinase family, is activated by a variety of stressful stimuli, including
exposure to cytotoxic agents. In their system, exposure to doxoru-
bicin resulted in increased JNK activity and increased MDR1
mRNA levels. Rohlff and Glazer (1995) suggested a number of
signalling pathways may act on MDR1 gene expression. Which, if
any, of these pathways are involved in the induction response
observed in our line is the focus of further work in our laboratory.
ABBREVIATIONS
IDA, 4-demethoxydaunorubicin (Idarubicin); MX2, 3¢-deamino-
3¢-morpholino-13-deoxo-10-hydroxycarminomycin; EPI, epiru-
bicin; DOX, doxorubicin; 5-FU, 5-fluorouracil; CyA, cyclosporin
A; Vp, verapamil; MDR, multidrug resistance; Pgp, P-glyco-
protein; mcf, mean channel fluorescence.
836 XF Hu et al
British Journal of Cancer (1999) 79(5/6), 831–837 © Cancer Research Campaign 1999ACKNOWLEDGEMENT
This study was supported in part by the Anti-Cancer Council of
Victoria and Department of Veterans Affairs, Canberra, Australia.
REFERENCES
Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C and Sikic BI (1995)
Decreased mutation rate for cellular resistance to doxorubicin and suppression
of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87:
1593–1602
Berman E (1993) A review of idarubicin in acute leukemia. Oncology 7: 91–104
Berman E and McBride M (1992) Comparative cellular pharmacology of
daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Blood 79 (1): 3267–3273
Bosch I and Croop J (1996) P-glycoprotein multidrug resistance and cancer. Biochim
Biophys Acta 1288: F37–F54
Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M,
Iacopino P, Mirto S, Pagano L, Leoni F, Martelli FM, Raimondo FD, Porcellini
A, de Rui L, Nosari AM, Cimino R, Damasio E, Miraglia E, Fioritoni G,
Ricciuti F, Carotenuto M, Longinotti M, Defazio D, Fazi P and Mandelli F
(1993) Idarubicin in combination with intermediate-dose cytarabine and Vp-16
in the treatment of refractory or rapidly relapsed patients with acute myeloid
leukemia. Leukemia 7: 196–199
Chaudhary PM and Roninson IB (1993) Induction of multidrug resistance in human
cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer
Inst 85: 632–639
Chen G, Jaffrézou JP, Fleming WH, Durán GE and Sikie BI (1994) Prevalence of
multidrug resistance related to activation of the MDR1 gene in human sarcoma
mutants derived by single-step doxorubicin selection. Cancer Res 54:
4980–4987
Chin KV, Chauhan SS, Pastan I and Gottesman MM (1990) Regulation of mdr RNA
levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1:
361–365
Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid
guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:
156–159
Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Soler RP and
Andreeff M (1996) The novel anthracycline annamycin is not affected by P-
glycoprotein related multidrug resistance: comparison with idarubicin and
doxorubicin in HL60 leukemia cell lines. Blood 88: 633–644
de Vries EGE and Zijlstra JG (1990) Morpholinyl anthracyclines: option for reversal
of anthracycline resistance. Eur J Cancer 26: 659–660
Deuchars KL and Ling V (1989) P-glycoprotein and multidrug resistance in cancer
chemotherapy. Semin Oncol 16: 156–165
Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L and Sikic BI (1996)
Resistance mechanisms in human sarcoma mutants derived by single-step
exposure to paclitaxel (Taxol). Cancer Res 56: 1091–1097
Fardel O, Lecureur V, Daval S, Corlu A and Guillouzo A (1997) Up-regulation of
P-glycoprotein expression in rat liver cells by acute doxorubicin treatment.
Eur J Biochem 246: 186–192
Ferrandis E and Benard J (1993) Activation of the human MDR1 gene promoter in
differentiated neuroblasts. Int J Cancer 54: 987–991
Gekeler V, Beck J, Noller A, Wilisch A, Fresc G, Neumann M, Handgretinger R,
Ehninger G, Probst H, Neithammer D (1994) Drug-induced changes in the
expression of MDR-associated gene: investigations on cultured cell lines and
chemotherapeutically treated leukemias. Ann Hematol 69: S19–S24
Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ
and Dalton WS (1993) P-glycoprotein expression in human plasma cell
myeloma: correlation with prior chemotherapy. Blood 81: 490–495
Hargave RM, Davey MW, Davey RA, Kidman AD (1995) Development of drug
resistance is reduced with idarubicin relative to other anthracyclines. Anti-
Cancer Drugs 6: 432–437
Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis
TJ, Kasahara K, Sasaki Y, Takahashi T and Saijo N (1990). 3¢-Deamino-3¢-
morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance
by rapid influx following higher frequency of formation of DNA single- and
double-strand breaks. Cancer Res 50: 4698–4701
Hu XF, de Luise M, Martin TJ and Zalcberg JR (1990b) Effect of cyclosporin
and verapamil on the cellular kinetics of daunorubicin. Eur J Cancer 26:
814–817
Hu XF, Martin TJ, Bell DR, de Luise M and Zalcberg JR (1990a) Combined use of
cyclosporin A and verapamil in modulating multidrug resistance in human
leukemia cell lines. Cancer Res 50: 2953–2957
Hu XF, Slater S, Wall DM, Kantharidis P, Parkin JD, Cowman A and Zalcberg JR
(1995) Rapid upregulation of mdr1 expression by anthracyclines in a classical
multidrug-resistant cell line. Br J Cancer 71: 931–936
Hu XF, Slater A, Wall DM, Parkin JD, Kanthrarids P and Zalcberg JR (1996)
Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by
anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res 2:
713–720
Kohno K, Sato S, Takano H, Matsuo K-I and Kuwano M (1989) The direct
activation of human multidrug resistance gene (MDR1) by anticancer agents.
Biochem Biophys Res Commun 165: 1415–1421
Manzano RG, Wright VK and Twentyman PR (1996) Rapid recovery of a functional
MDR phenotype caused by MRP after a transient exposure to MDR drugs in a
revertant human lung cancer cell line. Eur J Cancer 32A: 2136–2141
Michieli M, Michelutti A, Damiani D, Pipan C, Paspadori D, Lauria F and Baccarani
M (1993) A comparative analysis of the sensitivity of multidrug resistant
(MDR) and non-MDR cells to different anthracycline derivatives. Leukemia
Lymphoma 9: 255–264
Mickenna SL and Padua RA (1997) Review: multidrug resistance in leukemia. Br J
Haematol 96: 659–674
Nielsen C, Maare C and Skovesgaard T (1996) Cellular resistance to anthracyclines.
Gen Pharmacol 27: 251–255
Nooter K and Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in
haematological malignancies. Leukemia Res 18: 233–243
Osborn MT and Chambers TC (1996) Role of the stress-activated/c-jun NH2-
terminal protein kinase pathway in cellular response to adriamycin and other
chemotherapeutic drugs. J Biol Chem 271: 30950–30955
Poeta GD, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M,
Tribalto M, Amadori S and Papat G (1996) Clinical relevance of P-
glycoprotein expression in de novo acute myeloid leukemia. Blood 87:
1997–2004
Rohlff C and Glazer RI (1995) Regulation of multidrug resistance through the
c-AMP and EGF signalling pathways. Cell Signalling 7: 431–443
Ross DD, Doyle LA, Yang W, Tong Y and Cornblatt B (1995) Susceptibility of
idarubicin, daunorubicin and their C-13 alcohol metabolites to transport-
mediated multidrug resistance. Biochem Pharmacol 50: 1673–1683
Rothenberg M, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack D and Fojo AT
(1989) Expression of the mdr1/P-170 gene in patients with acute lymphoblastic
leukemia. Blood 74: 1388–1395
Shustik C, Dalton W and Gros P (1995) P-glycoprotein-mediated multidrug
resistance in tumor cells; biochemistry, clinical relevance and modulations. In
Molecular Aspects of Medicine, pp. 1–78. Elsvier Science: London
Tanimura H, Kohno K, Sato S-i, Uchiumi T, Miyazaki M, Kobayashi M and
Kuwano M (1992) The human multidrug resistance 1 promoter has an element
that responds to serum starvation. Biochem Biophys Comm 183: 917–924
Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y (1981) Overcoming of vincristine
resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity
of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972
Ueda K, Clark DP, Chen C-J, Roninson IB, Gottesman MM and Pastan I (1987) The
human multidrug resistance (mdr1) gene: cDNA cloning and transcription
initiation. J Biol Chem 262: 505–508
Watanabe M, Komeshima N, Naito M, Isoe T, Otake N and Tsuruo T (1991) Cellular
pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic
drug-resistant cells. Cancer Res 51: 157–161
Zalcberg JR, Hu XF, Wall DM, Mirski S, Cole S, Nadalin G, De Luise M, Parkin JD,
Vrazas V, Campbell L and Kantharidis P (1994) Cellular and karyotypic
characterization of two doxorubicin resistant cell lines isolated from the same
parental human leukemia cell line. Int J Cancer 57: 522–528
MDR1 induction by anthracycline analogues 837
British Journal of Cancer (1999) 79(5/6), 831–837 © Cancer Research Campaign 1999